



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Paul G. Genever
paul.genever@york.ac.uk
Alasdair G. Kay
alsadair.g.kay@york.ac.uk

SPECIALTY SECTION
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology

RECEIVED 29 November 2022
ACCEPTED 30 November 2022
PUBLISHED 13 December 2022

CITATION
Kay AG, Fox JM, Hewitson JP,
Stone AP, Robertson S, James S,
Wang X-n, Kapasa E, Yang XB and
Genever PG (2022) Corrigendum:
CD317-Positive Immune Stromal
Cells in Human “Mesenchymal
Stem Cell” Populations.
Front. Immunol. 13:1111042.
doi: 10.3389/fimmu.2022.1111042

COPYRIGHT
© 2022 Kay, Fox, Hewitson, Stone,
Robertson, James, Wang, Kapasa, Yang
and Genever. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations

Alasdair G. Kay^{1*}, James M. Fox¹, James P. Hewitson¹,
Andrew P. Stone¹, Sophie Robertson¹, Sally James¹,
Xiao-nong Wang², Elizabeth Kapasa³, Xuebin B. Yang³
and Paul G. Genever^{1*}

¹York Biomedical Research Institute and Department of Biology, University of York, York, United Kingdom, ²Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom, ³Department of Oral Biology, School of Dentistry, University of Leeds, St James’s University Hospital, Leeds, United Kingdom

KEYWORDS

mesenchymal stromal cells, MSC subtypes, heterogeneity, immunomodulation, CD317, BST2, tetherin

A Corrigendum on

CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations.

By Kay AG, Fox JM, Hewitson JP, Stone AP, Robertson S, James S, Wang X-n, Kapasa E, Yang XB and Genever PG (2022) *Front. Immunol.* 13:903796. doi: 10.3389/fimmu.2022.903796

In the published article, there was an error in the **Acknowledgments** section. An acknowledgment that would have been included at the time of submission was not included due to inability to obtain the written approval required which has become available now.

A correction has been made to **Acknowledgments**. The section previously stated:

“The authors thank the staff and patients of Clifton Park Hospital for samples. We are grateful to the University of York Technology Facility for support with flow cytometry, cell sorting, confocal microscopy bioinformatics and proteomic analysis. We also thank the York Centre of Excellence in Mass Spectrometry. We thank Emily Taylor for assistance in isolating primary T cells”.

The corrected **Acknowledgments** appears below:

“The authors thank the staff and patients of Clifton Park Hospital for samples and Emily Taylor for assistance isolating primary T cells. We thank the University of York Technology

Facility for support with flow cytometry, cell sorting, confocal microscopy and proteomic analysis as well as the York Centre of Excellence in Mass Spectrometry. The authors thank Gillian Gough, MRes student at Newcastle University, for contributions to acquisition, analysis, and interpretation of skin explant data.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.